MINNEAPOLIS, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire) will release financial results for the third quarter 2025 after the close of trading on Monday, November 3. Inspire’s management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments. A webcast of the call will be accessible via the Investor Relations page of the Inspire website or through this link: Inspire's Q3 20 ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Inspire (INSP) To Contact Him Directly To Discuss Their Options If you purchased or acquired Inspire stock and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Oct. 03, 2025 (GLOBE NEWSWIRE) -- What’s Happening: Bragar Eagel & Squire, P.C., a nationally recognized ...

Summers Value Partners, an investment management company, released its second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The Summers Value Fund LP returned a net return of -1.8% net in Q2 2025, trailing the 8.5% return of the Russell 2000 Index ETF (IWM) and the 4.9% return for the Russell 2000 Value Index ETF (IWN). Year-to-date, the fund is down 12.8% net compared to (-1.8%) and (-3.2%) returns for the indexes, respectively. In addition, you can check the fund’s top 5 hold ...

Core Insights - Inspire Medical Systems, Inc. is facing challenges in the commercial rollout of its new Inspire V system, impacting revenue growth in 2025 due to delays in onboarding treatment centers and reimbursement processes [2][3] - The company is experiencing increased competition from GLP-1 drugs, which are FDA-approved for weight management and obstructive sleep apnea treatment, leading to reduced demand for its implantable devices [3] - Inspire has revised its 2025 sales forecast to a range of $900–$910 million, with CEO Tim Herbert indicating that the slower U.S. commercial launch and transition to Inspire V will affect annual financial performance [3] Company Developments - Despite current challenges, Inspire Medical Systems' Board has authorized a $200 million share buyback plan, indicating confidence in the company's long-term prospects [4] - The company plans a marketing push and expansion of treatment centers in the second half of 2025, which could enhance procedure volumes and revenue growth into 2026 [4] - CFO Rick Buchholz announced plans to transition to an advisory role at year-end to ensure a smooth leadership transition [4]

Group 1 - The event is a fireside chat hosted by Wells Fargo featuring the management team from Inspire Medical [1] - Participants include Carlton Weatherby, Chief Strategy and Growth Officer, and Ezgi Yagci, Vice President of Investor Relations [1][2] - The format of the discussion is a Q&A session, encouraging audience participation [2]

A month has gone by since the last earnings report for Inspire Medical Systems (INSP) . Shares have added about 7.5% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Inspire due for a pullback? Well, first let's take a quick look at the latest earnings report in order to get a better handle on the recent catalysts for Inspire Medical Systems, Inc. before we dive into how investors and analysts have reacted as of late.INSP Q2 ...

Financial Data and Key Metrics Changes - The company reported a guidance reduction of approximately 4.5% for the second half of the year, primarily driven by the transition to Inspire five, with a more significant impact of about 9% for the second half [13][14] - The management noted an increase in patient warehousing dynamics, indicating patients are waiting for Inspire five despite the availability of Inspire four, affecting the patient funnel [14][15] Business Line Data and Key Metrics Changes - The transition to Inspire five is progressing well, with surgeon training and certification reaching approximately 99%, up from 90% [4][5] - Contracting with implanting accounts has improved to over 80% from 70% [5] - The implementation of the Sleep Sync programmer has increased to about 65% from 50% [6][7] Market Data and Key Metrics Changes - The company expects to complete the transition from Inspire four to Inspire five by the end of the year, with full adoption anticipated across all implanting accounts [9] - The management highlighted that the coding issue related to Medicare has been resolved, removing a previous headwind [10][11] Company Strategy and Development Direction - Inspire five is seen as a catalyst for growth, with expectations of increased productivity and efficiency in procedures, allowing for more cases to be handled [29][30] - The company is focusing on expanding its footprint by adding more territory managers and field clinical representatives to support the growth of Inspire five [30][31] - Medical education is emphasized as a key growth vector, targeting both early career professionals and experienced surgeons [30] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, stating that the market opportunity is massive and underpenetrated, with a commitment to innovation and improved patient outcomes [80] - The impact of GLP-1 medications on patient dynamics is still being assessed, with both positive and negative effects observed [19][20] Other Important Information - The company is preparing to present data at upcoming conferences, showcasing the efficacy and operational efficiency of Inspire five [34][35] - Management acknowledged the competitive landscape, particularly with the introduction of new hypoglossal nerve stimulation devices, but remains confident in their product's advantages [45][46] Q&A Session Summary Question: What is the reason for the guidance reduction? - The guidance reduction is primarily due to the slower transition to Inspire five, which has led to patient warehousing dynamics and inventory destocking of Inspire four [14][15] Question: How is the company addressing competition from GLP-1 medications? - The management noted that while GLP-1s may delay some patients, they also create opportunities for new patients to enter the treatment funnel as they lose weight [19][20] Question: What are the expectations for Inspire five adoption? - Full adoption of Inspire five is expected by the end of the year, with significant progress already made in surgeon training and account readiness [9][32] Question: How does the company view the total addressable market (TAM)? - The management believes the TAM is growing, driven by increased awareness and diagnosis rates for obstructive sleep apnea [43] Question: What is the company's strategy regarding international markets? - While the focus remains on the U.S. market, the company is also exploring opportunities in international markets, particularly in Europe and Asia [74][75]

Financial Data and Key Metrics Changes - The company reported a guidance reduction of approximately 4.5% for the second half of the year, primarily driven by the transition to Inspire five, with a more significant impact of about 9% for the second half [13][15][40] - The company expects to complete the transition from Inspire four to Inspire five by the end of the year, with full adoption anticipated across all implanting accounts [9][30] Business Line Data and Key Metrics Changes - The transition to Inspire five has seen significant progress, with surgeon certification increasing from 90% to nearly 99%, and contract execution rising from 70% to over 80% [5][6] - The implementation of the Sleep Sync programmer has improved from 50% to approximately 65% of implanting accounts [6][7] Market Data and Key Metrics Changes - The company noted a "patient warehousing dynamic," where patients are waiting for Inspire five despite the availability of Inspire four, impacting the patient funnel [14][15] - The company anticipates that the dynamics of patient warehousing and inventory destocking will stabilize as the transition to Inspire five progresses [15][16] Company Strategy and Development Direction - Inspire Medical is focusing on expanding its market presence through the launch of Inspire five, which is expected to drive productivity and efficiency in procedures [27][28] - The company is also investing in medical education and training for surgeons and mid-level professionals to enhance patient outcomes and drive growth [29][30] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, stating that the market opportunity is massive and underpenetrated, with expectations for continued growth driven by Inspire five [80] - The company is also monitoring the impact of GLP-1 medications on patient dynamics, which could lead to both positive and negative effects on patient flow [20][21] Other Important Information - The company is preparing to present data at upcoming conferences, highlighting the safety and efficacy of Inspire five [34][36] - Management acknowledged the competitive landscape, particularly with the introduction of new hypoglossal nerve stimulation devices, but remains confident in the advantages of Inspire's offerings [45][46] Q&A Session Summary Question: Why was there a significant guidance reduction? - Management explained that the slower transition to Inspire five led to a backlog of patients waiting for the new product, impacting the patient funnel and resulting in a reduction in guidance [14][15] Question: How does the company view the impact of GLP-1 medications? - Management indicated that while GLP-1s could bring new patients into the funnel, they also cause delays as some patients trial these medications before considering Inspire therapy [20][21] Question: What is the company's strategy regarding competition? - Management welcomed competition as validation of market potential and emphasized the importance of maintaining high standards in safety and efficacy compared to new entrants [45][46] Question: What are the expectations for growth in the coming years? - Management expects growth to accelerate in the following year, driven by the full adoption of Inspire five and continued expansion of the company's footprint [60][61]

Company Overview - Inspire Medical Systems, Inc. is a medical technology company focused on developing and commercializing innovative, minimally invasive solutions for patients with obstructive sleep apnea [4] - The company's proprietary Inspire therapy is the first and only FDA, EU MDR, and PDMA-approved neurostimulation technology for treating moderate to severe obstructive sleep apnea [4] Leadership Change - Chief Financial Officer Rick Buchholz will step down effective December 31, 2025, to pursue other professional opportunities, but will remain in a financial advisory role until February 28, 2026, to ensure a smooth transition [1][2] - Buchholz has been with the company since 2014 and has played a significant role in its growth, including increasing revenue from $4 million to over $800 million in 2024 [2] Financial Guidance - The company reaffirms its full-year 2025 revenue guidance of $900 to $910 million, with a gross margin guidance of 84% to 86% and diluted net income per share guidance of $0.40 to $0.50 [3]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Inspire Medical Systems and its executives following a significant reduction in the company's financial outlook [1][3]. Financial Performance - On August 4, 2025, Inspire Medical Systems announced its second quarter financial results, revising its full-year revenue outlook to $900 million - $910 million and diluted net income per share to $0.40 - $0.50, down from previous guidance of $940 million - $955 million and $2.20 - $2.30 [3]. - The company attributed these reductions to slower-than-expected progress in the commercial launch of its next generation Inspire V neurostimulation system [3]. Market Reaction - Following the announcement of the revised financial outlook, Inspire's stock price experienced a significant decline, falling by $42.04 per share, or 32.35%, to close at $87.91 per share on August 5, 2025 [4].